Thrombosis
Science in Thrombosis
Get a 360º view and stay up-to-date on Thrombosis with content selected for you
.jpg/jcr:content/image%20(6).jpg)
Changing trends in VTE: Pulmonary Embolism cases on Rise within the Last Decade
Danish study finds more elderly and patients with comorbidities being diagnosed.
Evaluation Of Comparative Efficacy and Safety of Thromboprophylaxis Agents Among Critically Ill Patients
This systematic review and network meta-analysis revealed that the use of low-molecular-weight heparin (LMWH) may be more effective than unfractionated heparin (UFH) in reducing incidence of deep vein thrombosis (DVT) among critically ill patients.
Inspiration and innovation
Get inspired and stay at the forefront of innovation with the following resources
.png/jcr:content/thrombosis-sz-2022%20(1).png)
.png/jcr:content/th-thumb5%20(1).png)
.png/jcr:content/th-thumb4%20(1).png)
.png/jcr:content/th-thumb3%20(1).png)
Events
Stay up to date and register for the latest events and view webinar recordings.
Cardiovascular diseases (CVDs) are the leading cause of death globally1
According to the World Health Organization, an estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths1. Of these deaths, 85% were due to myocardial infarction or stroke1.
A CV event is a highly traumatic experience for patients and their families2. It takes a heavy emotional toll, brings widespread disability and significantly impedes quality of life3,4.
.webp/jcr:content/Lipid-lowering-therapy-thumb%20(2).webp)
